Focus Financial Network Inc. Has $5.69 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Focus Financial Network Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,135 shares of the company’s stock after selling 704 shares during the quarter. Focus Financial Network Inc.’s holdings in Johnson & Johnson were worth $5,694,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Golden Road Advisors LLC bought a new position in Johnson & Johnson during the third quarter worth about $214,000. Principal Securities Inc. boosted its stake in shares of Johnson & Johnson by 13.8% during the 3rd quarter. Principal Securities Inc. now owns 34,881 shares of the company’s stock worth $5,653,000 after acquiring an additional 4,232 shares during the period. Stephens Inc. AR increased its holdings in shares of Johnson & Johnson by 27.1% during the 3rd quarter. Stephens Inc. AR now owns 201,555 shares of the company’s stock worth $32,664,000 after acquiring an additional 42,989 shares during the last quarter. Norris Perne & French LLP MI raised its stake in Johnson & Johnson by 21.4% in the 3rd quarter. Norris Perne & French LLP MI now owns 187,222 shares of the company’s stock valued at $30,341,000 after acquiring an additional 33,018 shares during the period. Finally, Lincluden Management Ltd. lifted its holdings in Johnson & Johnson by 1.4% during the 3rd quarter. Lincluden Management Ltd. now owns 13,874 shares of the company’s stock valued at $2,248,000 after purchasing an additional 189 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $160.13 on Friday. The company’s 50-day moving average price is $163.31 and its two-hundred day moving average price is $155.44. The firm has a market cap of $385.53 billion, a P/E ratio of 23.17, a P/E/G ratio of 2.85 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.66 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Finally, Citigroup upped their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.93.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.